Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C39H48N4O4 |
| Molecular Weight | 636.8228 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCOC(C)C1=C2NC(C=C3N=C([C@@H](CCC(O)=O)[C@@H]3C)C4=C5NC(=CC6=NC(=C2)C(C)=C6CC)C(C)=C5C(=O)C4)=C1C
InChI
InChIKey=PVXGCBZIVFCMJK-NMWXTPPCSA-N
InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,41,43H,8-16H2,1-7H3,(H,45,46)/b28-19-,29-17-,30-17-,31-18-,32-18-,33-19-,38-27-/t21-,24?,26-/m0/s1
| Molecular Formula | C39H46N4O4 |
| Molecular Weight | 634.8069 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH), a chlorin-based photosensitize, is used in photodynamic therapy. It has been shown the therapeutic potential of HPPH in phase II clinical trials for the treatment of esophageal cancer. Besides, HPPH participated in clinical trials in treating patients with advanced non-small cell lung cancer that blocks the air passages. However, these studies were terminated.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. | 1994 Sep-Oct |
|
| Stereoselective determination of p-hydroxyphenyl-phenylhydantoin enantiomers in rat liver microsomal incubates by reversed-phase high-performance liquid chromatography using beta-cyclodextrin as chiral mobile phase additives. | 2001 Apr |
|
| Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. | 2001 Apr |
|
| Effect of mild therapeutic hypothermia on phenytoin pharmacokinetics. | 2001 Jun |
|
| Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. | 2001 Oct |
|
| Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. | 2001 Oct 23 |
|
| Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. | 2002 Nov |
|
| Key structural features of ligands for activation of human pregnane X receptor. | 2004 Apr |
|
| Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases. | 2005 Apr |
|
| Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650 analyzer: effect of phenytoin metabolite and analogue. | 2005 Jun |
|
| The effects of phenytoin and its metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin on cellular glucose transport. | 2005 Mar 4 |
|
| CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. | 2005 Nov |
|
| Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. | 2006 May |
|
| Studies by biointeraction chromatography of binding by phenytoin metabolites to human serum albumin. | 2006 May 19 |
|
| Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. | 2006 Sep |
|
| Stereoselective glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions. | 2007 Sep |
|
| High-performance liquid chromatographic method for determination of phenytoin in rabbits receiving sildenafil. | 2008 Apr 18 |
|
| Phenytoin metabolite renal calculus: an index case. | 2008 Aug |
|
| CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry. | 2009 Jun |
|
| Determination of phenytoin and its major metabolite in human serum by MEKC. | 2009 Nov-Dec |
|
| Suppression of LPS-induced matrix-metalloproteinase responses in macrophages exposed to phenytoin and its metabolite, 5-(p-hydroxyphenyl-), 5-phenylhydantoin. | 2010 Sep 15 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:55:07 GMT 2023
by
admin
on
Fri Dec 15 15:55:07 GMT 2023
|
| Record UNII |
DOB7Y3RSX0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
640418
Created by
admin on Fri Dec 15 15:55:07 GMT 2023 , Edited by admin on Fri Dec 15 15:55:07 GMT 2023
|
||
|
NCI_THESAURUS |
C1420
Created by
admin on Fri Dec 15 15:55:07 GMT 2023 , Edited by admin on Fri Dec 15 15:55:07 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
149402-51-7
Created by
admin on Fri Dec 15 15:55:07 GMT 2023 , Edited by admin on Fri Dec 15 15:55:07 GMT 2023
|
PRIMARY | |||
|
DTXSID501028872
Created by
admin on Fri Dec 15 15:55:07 GMT 2023 , Edited by admin on Fri Dec 15 15:55:07 GMT 2023
|
PRIMARY | |||
|
DOB7Y3RSX0
Created by
admin on Fri Dec 15 15:55:07 GMT 2023 , Edited by admin on Fri Dec 15 15:55:07 GMT 2023
|
PRIMARY | |||
|
DB15243
Created by
admin on Fri Dec 15 15:55:07 GMT 2023 , Edited by admin on Fri Dec 15 15:55:07 GMT 2023
|
PRIMARY | |||
|
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
Created by
admin on Fri Dec 15 15:55:07 GMT 2023 , Edited by admin on Fri Dec 15 15:55:07 GMT 2023
|
PRIMARY | |||
|
C2636
Created by
admin on Fri Dec 15 15:55:07 GMT 2023 , Edited by admin on Fri Dec 15 15:55:07 GMT 2023
|
PRIMARY |